S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

OSTX OS Therapies Incorporated

1.6101

-0.0299 (-1.82%)

Feb 28 2025 - Closed

Delayed by 15 minutes

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more OS Therapies Charts.

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more OS Therapies Charts.

OS Therapies Incorporated News

Form 4 - Statement of changes in beneficial ownership of securities
Friday 28 February 2025 (15 hours ago) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Friday 28 February 2025 (15 hours ago) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Friday 28 February 2025 (15 hours ago) • Edgar (US Regulatory)

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
Wednesday 26 February 2025 (3 days ago) • Business Wire

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Monday 24 February 2025 (5 days ago) • Business Wire

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Thursday 20 February 2025 (1 week ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 18 February 2025 (1 week ago) • Edgar (US Regulatory)

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
Friday 14 February 2025 (2 weeks ago) • Business Wire

Form PRE 14A - Other preliminary proxy statements
Friday 7 February 2025 (3 weeks ago) • Edgar (US Regulatory)

OS Therapies Provides Corporate Update
Tuesday 4 February 2025 (4 weeks ago) • Business Wire

Form S-1 - General form for registration of securities under the Securities Act of 1933
Friday 31 January 2025 (4 weeks ago) • Edgar (US Regulatory)

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
Wednesday 29 January 2025 (1 month ago) • Business Wire

More OS Therapies Incorporated News Articles

VanEck Emerging Markets ...

Tamarack Valley Energy (PK)

Equity Residential

Molecular Partners (CE)

Amundi Msci Ex Usa Mega ...

Exchange Traded

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions